title: Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.
abstract: Patients with atrial fibrillation have an increased risk for stroke, systemic embolism and cardiovascular events, including myocardial infarction and cardiovascular death. However, the majority of studies that have analyzed the efficacy of anticoagulants have been focused only on their effects on the risk of stroke. Areas covered: The available evidence about the association between atrial fibrillation and cardiovascular disease as well as the effects of oral anticoagulation on cardiovascular death and myocardial infarction, with a particular focus on direct oral anticoagulants, was updated in this review. Expert opinion: The management of patients with atrial fibrillation should not be limited to the prevention of stroke, but should also include the prevention of cardiovascular events. Despite treatment with vitamin K antagonists, many patients with atrial fibrillation still develop cardiovascular complications, particularly individuals whose anticoagulation is difficult to control. Direct oral anticoagulants overcome the majority of limitations of vitamin K antagonists and compared with warfarin, they lead to a greater reduction in the risk of stroke or systemic embolism, all-cause mortality, and intracranial hemorrhage. Although these drugs can only be compared indirectly, it seems that not all direct oral anticoagulants are equal with regard to the prevention of myocardial infarction.
authors.affiliation: a Department of Cardiology , Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca , Murcia , Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
authors.affiliation: b Department of Cardiology , Hospital Universitario Reina Sofía , Córdoba , Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Anguita-Sánchez
authors.affiliation: c Jefe de Sección SCA. H.U. Ramón y Cajal , Madrid , Spain.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Sanmartín
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004617:Embolism / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control; D020521:Stroke / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin
keywords: Apixaban; atrial fibrillation; cardiovascular; dabigatran; direct oral anticoagulants; edoxaban; myocardial infarction; rivaroxaban; warfarin